title: The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome.
abstract: OBJECTIVE
  To evaluate the effect of oral contraceptive pills (OCP) pretreatment on IVF cycle outcome in GnRH-antagonist protocol.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Major tertiary university-affiliated center.
  
  
  METHODS
  All patients treated with GnRH antagonist in our IVF unit during the last 3 years were included in the study. Overall 1,799 IVF cycles were performed. Of these, in 604 cycles OCP pretreatment was used prior to GnRH-antagonist for cycle scheduling. Patients were divided into two age groups-young group aged < or = 35 years and older group aged > or = 36 years.
  
  
  METHODS
  The young group underwent 927 cycles, 281 cycles with OCP pretreatment and 646 cycles without. The older group underwent 872 cycles, 323 cycles with OCP pretreatment and 549 cycles without. Data was analyzed within each age group.
  
  
  METHODS
  Treatment duration and total dose of FSH IU used for stimulation, number of oocytes retrieved, implantation and pregnancy rates.
  
  
  RESULTS
  All OCP-pretreated cycles required significantly longer stimulation than non-pretreated cycles (young: 10.76 vs. 9.21 days; older: 10.48 vs. 8.73 days, respectively) and higher total dose of FSH IU (young: 3,210 IU vs. 2,565 IU; older: 4,973 IU vs. 3,983 IU, respectively). There were no other differences in cycle characteristics between groups. Implantation and pregnancy rates were not affected by OCP pretreatment.
  
  
  CONCLUSIONS
  OCP pretreatment can be offered as a mode for cycle scheduling prior to GnRH-antagonist protocol, though it may be associated with longer stimulation and higher gonadotropin consumption.
authors.affiliation: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. haimpin@clalit.org.il
authors.forename: Haim
authors.initials: H
authors.lastname: Pinkas
authors.forename: Onit
authors.initials: O
authors.lastname: Sapir
authors.forename: Ori M
authors.initials: OM
authors.lastname: Avrech
authors.forename: Avi
authors.initials: A
authors.lastname: Ben-Haroush
authors.forename: Jacob
authors.initials: J
authors.lastname: Ashkenzi
authors.forename: Benjamin
authors.initials: B
authors.lastname: Fisch
authors.forename: Jacob
authors.initials: J
authors.lastname: Farhi
mesh_terms: D000328:Adult; D015331:Cohort Studies; D003276:Contraceptives, Oral / Q000627:therapeutic use*; D010064:Embryo Implantation; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007246:Infertility; D008297:Male; D009865:Oocytes / Q000166:cytology / Q000502:physiology; D010062:Ovulation Induction; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies
chemical_list: D003276:Contraceptives, Oral; D007987:Gonadotropin-Releasing Hormone